Market Research Report
Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2028
|Published by||DelveInsight Business Research LLP||Product code||602068|
|Published||Content info||100 Pages
Delivery time: 1-2 business days
|Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2028|
|Published: January 1, 2019||Content info: 100 Pages||
DelveInsight's 'Herpes Simplex Virus (HSV) Infections - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of HSV infections in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of HSV infections from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2016-2028
The DelveInsight HSV infections market report gives the thorough understanding of HSV infections by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for HSV infections in the US, Europe, and Japan.
The HSV infections epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalent cases by types (Genital Herpes and Herpes Labialis), diagnosed prevalence] of HSV infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.
According to DelveInsight, total prevalent population of HSV infections in 7 major markets were estimated to be 228,552,199 in 2016.
This segment of the HSV infections report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current HSV Virus infections market is dependent on antiviral drugs that are not the cure of the disease but relief the symptoms of the disease and in long-term reduces the incidence of relapses if started before exposure to the triggering conditions. Although, antiviral therapies have proven its effectiveness in this market associated complications and need of a cure demands the emergence of novel therapy. Detailed chapter for upcoming therapies Pritelivir (AiCuris), SQX770 (Squarex), BTL TML HSV (Beech Tree Labs), GEN 003 (Genocea Biosciences), VCL-HB01 (Vical) and M5210B (Maruho) have been covered in the report.
The HSV Infections market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of HSV Infections in 7MM was found to be USD 4 Billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.